Who
Jeremy Bender
Director
Company insider
Files Form 4 as: Director, Bicara Therapeutics; Director, Aura Biosciences; Chief Executive Officer, Day One Biopharmaceuticals; Director, Mereo BioPharma Group; Director, Fusion Pharmaceuticals.
In numbers
- Trades disclosed
- 236
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $5.6M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 18 Jan 2022
- Last trade
- 28 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 29 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,950 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,950 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One BiopharmaceuticalsBiotechnology | SEC FORM 4 Code D | —204,643 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —244,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —286,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —286,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —355,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,250 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —81,816 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —128,565 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —222,188 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One BiopharmaceuticalsBiotechnology | SEC FORM 4 Code D | —20,204 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One BiopharmaceuticalsBiotechnology | SEC FORM 4 Code D | —300,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,463,134 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —397,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —244,000 | filing |
News
No headline names them, or the companies they trade most, lately.